A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes

What Was Tested

This randomized controlled trial paper looks at Insulin Glargine and Insulin Aspart.

Who Took Part

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

Patients with a diagnosis of T2DM for > or = 12 months who had been receiving an OAD or insulin, with or without OADs, for > 4 months were randomized in a 2:1 ratio to receive detemir or glargine.

How the Study Was Run

In design terms this was a randomized and parallel-group study.

Because people in this Insulin Glargine study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The Insulin Glargine group and the comparison group ran side by side rather than switching.

According to the approved labeling, detemir could be administered once or twice daily, and glargine was administered once daily.

Insulin aspart was given at mealtimes.

Insulin secretagogues and a-glucosidase inhibitors were discontinued at study entry, and existing OADs were continued.

Safety end points included the frequency of hypoglycemia and adverse events (AEs).

What Was Measured

The subject headings attached to it are Blood Glucose, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hypoglycemia, Hypoglycemic Agents, Insulin and Insulin Detemir.

What This Means in Plain Language

The paper is a randomized and parallel-group study of Insulin Glargine and Insulin Aspart.

Results are reported in around 14 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2008 (Clinical therapeutics), a journal based in United States.

More context: the Insulin Glargine compound page and the Insulin Aspart compound page.